Treatment with these Tregs, especially those which are noncanonical, leads to attenuation of GVHD with preservation of GVL effects, suggesting that inhibiting Itk may be a potential therapeutic target for treatment of GVHD and other diseases where Tregs are therapeutically useful. Here, ITK is linked to graft versus host disease.